



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 39/395, C12P 21/00		A1	(11) International Publication Number: WO 89/ 06975 (43) International Publication Date: 10 August 1989 (10.08.89)
(21) International Application Number: PCT/US89/00285 (22) International Filing Date: 30 January 1989 (30.01.89) (31) Priority Application Number: 151,413 (32) Priority Date: 2 February 1988 (02.02.88) (33) Priority Country: US (71) Applicant: SCHERING BIOTECH CORPORATION [US/US]; 901 California Avenue, Palo Alto, CA 94304-1104 (US). (72) Inventors: COFFMAN, Robert, L. ; 239 Echo Lane, Portolo Valley, CA 94025 (US). DE VRIES, Jan, Egbert ; 6C, chemin du Trouyllat, F-69130 Ecully (FR). (74) Agents: BLASDALE, John, H. et al.; Schering-Plough Corporation, One Giralda Farms, Madison, NJ 07940-1000 (US).		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD OF REDUCING IMMUNOGLOBULIN E RESPONSES			
(57) Abstract			
<p>A method of reducing immunoglobulin E responses associated with certain immune disorders is provided. The method comprises administering an effective amount of an antagonist to human interleukin-4. Preferably the antagonist is a blocking monoclonal antibody specific for human interleukin-4, or a fragment or binding composition derived therefrom.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

METHOD OF REDUCING IMMUNOGLOBULIN E RESPONSES

The invention relates generally to a method for treating immune disease associated with excessive production of immunoglobulin E (IgE) and, more particularly, to a method of reducing IgE production by inhibiting the action of interleukin-4.

As far as can be determined, the main physiological function of IgE-mediated responses is to combat parasites. The response can be divided into five phases: an IgE-bearing B cell is stimulated to respond to an antigen (phase 1) and activated to secrete IgE antibodies (phase 2); the produced antibodies bind to mast cells and basophils in tissue (phase 3, antibody fixation), interaction of antigen with cell-bound IgE activates these cells, and causes the release of chemical mediators stored in their granules (phase 4, degranulation); and finally, the mediators induce a complex tissue response aimed at the elimination of nonmicrobial parasites from the body (phase 5). Part of this defense mechanism is an attack on the tissue that harbors the parasite--that is, on self. To excise a parasite from a tissue without damaging the rest of the body is an extraordinarily delicate act. The mediators released by activated mast cells and basophils can cause considerable harm, even death, if released at an inappropriate time or

-2-

if directed at an inappropriate target. The IgE response must be closely controlled and quickly attenuated after its goal has been achieved. As long as this control is functioning there is no danger that healthy parts of the body will be damaged, but, should the controls fail, the beneficial reaction will turn into a harmful one. About 90 percent of all humans have no difficulty in using their IgE only for defensive purposes; but the remaining unlucky 10 percent carry a genetic defect of the control mechanism that permits the stimulation of IgE responses by antigens that have nothing to do with parasites. At first it was thought that this defect was limited only to humans, but similar defects were discovered later in several other mammals. The inappropriately stimulated IgE responses cause a plethora of diverse diseases, grouped under the name allergy or atopy; see Klein, Immunology: The Science of Self-Nonself Discrimination (John Wiley & Sons, New York, 1982).

Currently glucocorticoid steroids are the most effective drugs for treating allergic diseases. However, prolonged steroid treatment is associated with many deleterious side effects: Goodman and Gilman, The Pharmacological Basis of Therapeutics, 6th Ed. (MacMillan Publishing Company, New York, 1980). Consequently, the availability of alternative approaches to the treatment of immune disorders associated with excessive IgE production could have important clinical utility.

The invention therefore provides a method of reducing levels of IgE by administering an effective amount of an antagonist to human interleukin-4 (IL-4). A preferred antagonist to IL-4 is a monoclonal antibody, or binding compositions derived therefrom by standard techniques.

The antagonist to human interleukin-4 is preferably a monoclonal antibody capable of blocking the

-3-

immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, or a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.

The invention is based on the discovery that IL-4 increases the production of IgE in humans. The method of the invention therefore comprises administering to a patient an effective, or disease-ameliorating amount, of an antagonist to human IL-4.

Preferably, the antagonists of the invention are derived from antibodies specific for human IL-4. More preferably, the antagonists of the invention comprise fragments or binding compositions specific for IL-4.

Antibodies comprise an assembly of polypeptide chains linked together by disulfide bridges. Two major polypeptide chains, referred to as the light chain and the heavy chain, make up all major structural classes (isotypes) of antibody. Both heavy chains and light chains are further divided into subregions referred to as variable regions and constant regions. Heavy chains comprise a single variable region and three different constant regions, and light chains comprise a single variable region (different from that of the heavy chain) and a single constant region (different from those of the heavy chain). The variable regions of the heavy chain and light chain are responsible for the antibody's binding specificity.

As used herein, the term "heavy chain variable region" means a polypeptide (1) which is from 110 to 125 amino acids in length (the number starting from the heavy

-4-

chain's N-terminal amino acid), and (2) whose amino acid sequence corresponds to that of a heavy chain of a monoclonal antibody of the invention. Likewise, the term "light chain variable region" means a polypeptide (1) which is from 95 to 115 amino acids in length (the numbering starting from the light chain's N-terminal amino acid), and (2) whose amino acid sequence corresponds to that of a light chain of a monoclonal antibody of the invention.

As used herein the term "monoclonal antibody" refers to homogenous populations of immunoglobulin which are capable of specifically binding to human IL-4.

As used herein the term "binding composition" means a composition comprising two polypeptide chains (1) which, when operationally associated, assume a conformation having high binding affinity for human interleukin-4, and (2) which are derived from a hybridoma producing monoclonal antibodies specific for human interleukin-4. The term "operationally associated" is meant to indicate that the two polypeptide chains can be positioned relative to one another for binding by a variety of means, including association in a native antibody fragment, such as Fab or Fv, or by way of genetically engineered cysteine-containing peptide linkers at the carboxyl termini. Normally, the two polypeptide chains correspond to the light chain variable region and heavy chain variable region of a monoclonal antibody specific for human interleukin-4.

Preferably, antagonists of the invention are derived from monoclonal antibodies specific for human IL-4. Monoclonal antibodies capable of blocking IgE-enhancing activity of IL-4 are selected in standard in vitro assays for IL-4 based on T cell proliferation; e.g. Yokota et al. (cited above). It has been observed in murine systems that all biological activities of IL-4 can

-5-

be blocked by a single monoclonal antibody. Thus, it is believed that all the activities are mediated by a single site, i.e. the receptor binding site, on the protein.

Hybridomas of the invention are produced by well-known techniques. Usually, the process involves the fusion of an immortalizing cell line with a B-lymphocyte which produces the desired antibody. Alternatively, non-fusion techniques for generating immortal antibody-producing cell lines are possible, and come within the purview of the present invention; e.g. virally induced transformation: Casali et al., "Human Monoclonals from Antigen-Specific Selection of B Lymphocytes and Transformation by EBV," Science, Vol. 234, pgs. 476-479 (1986). Immortalizing cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, or human origin. Most frequently, rat or mouse myeloma cell lines are employed as a matter of convenience and availability.

Techniques for obtaining the appropriate lymphocytes from mammals injected with the target antigen are well known. Generally, either peripheral blood lymphocytes (PBLs) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. A non-human host mammal is injected with repeated dosages of the purified antigen, and the mammal is permitted to generate the desired antibody-producing cells before these are harvested for fusion with the immortalizing cell line. Techniques for fusion are also well known in the art, and in general involve mixing the cells with a fusing agent, such as polyethylene glycol. Hybridomas are selected by standard procedures, such as HAT selection. Human-human hybridomas are especially preferred. From among these hybridomas, those secreting the desired antibody are selected by assaying their culture medium by standard

-6-

immunoassays, such as Western blotting, ELISA, RIA, or the like. Antibodies are recovered from the medium using standard protein purification techniques; e.g. Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985). Many references are available for guidance in applying any of the above techniques; e.g. Kohler et al., Hybridoma Techniques (Cold Spring Harbor Laboratory, New York, (1980); Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985); Campbell, Monoclonal Antibody Technology (Elsevier, Amsterdam, 1984); Hurrell, Monoclonal Hybridoma Antibodies: Techniques and Applications (CRC Press, Boca Raton, FL, 1982); and the like.

The use and generation of fragments of antibodies is also well known, e.g. Fab fragments: Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985); and Fv fragments. Hochman et al., Biochemistry, Vol. 12, pgs. 1130-1135 (1973), Sharon et al., Biochemistry, Vol. 15, pgs 1591-1594 (1976), and Ehrlich et al., U.S. Patent 4,355,023; and antibody half-molecules: Auditore-Hargreaves, U.S. Patent 4,470,925. Moreover, such compounds and compositions of the invention can be used to construct bi-specific antibodies by known techniques; e.g., further fusions of hybridomas (i.e. to form so-called quadromas) -- see Reading, U.S. Patent 4,474,493; or chemical reassociation of half-molecules -- see Brennan et al., Science, Vol. 229, pgs. 81-83 (1985).

Hybridomas and monoclonal antibodies of the invention are produced against either glycosylated or unglycosylated versions of recombinantly-produced mature human interleukin-4. Generally, unglycosylated versions of human IL-4 are produced in E. coli and glycosylated versions are produced in mammalian cell hosts, e.g. CV1

-7-

or COS monkey cells, mouse L cells, or the like. Recombinantly produced mature human IL-4 is produced by introducing an expression vector into a host cell using standard protocols; e.g. Maniatis et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, New York, 1982); Okayama and Berg, Mol. Cell. Biol., Vol 2, pgs 161-170 (1982) and Vol. 3, pgs. 280-289 (1983); Hamer, Genetic Engineering, Vol. 2, pgs. 83-100 (1980) and U.S. Patent 4,599,308; Kaufman et al., Mol. Cell. Biol., Vol. 2, pgs. 1304-1319 (1982); or the like.

Construction of bacterial or mammalian expression vectors is well known in the art, once the nucleotide sequence encoding a desired protein is known or otherwise available; e.g. DeBoer in U.S. Patent 4,551,433 discloses promoters for use in bacterial expression vectors; Goeddel et al. in U.S. Patent 4,601,980, and Riggs in U.S. Patent 4,431,739 disclose the production of mammalian proteins by E. coli expression systems; and Riggs (cited above), Ferretti et al., Proc. Natl. Acad. Sci., Vol. 83, pgs 599-603 (1986), Sproat et al., Nucleic Acids Research, Vol. 13, pgs. 2959-2977 (1985), and Mullenbach et al., J. Biol. Chem., Vol. 261, pgs. 719-722 (1986) disclose how to construct synthetic genes for expression in bacteria. Accordingly, these references are incorporated by reference. The amino acid sequence of mature human IL-4 is disclosed by Yokota et al. (cited above), and the cDNA encoding human IL-4 carried by the pcD vector described by Yokota et al. (cited above) is deposited with the American Type Culture Collection (ATCC), Rockville, MD, under accession number 67029. Many bacterial expression vectors and hosts are available commercially and through the ATCC. Preferably, human IL-4 for immunizing host animals is isolated from culture supernatants of COS, CV1, or mouse L cells which have been transiently transfected by the above-mentioned pcD vector.

-8-

Antibodies and antibody fragments characteristic of hybridomas of the invention can also be produced by recombinant means by extracting messenger RNA, constructing a cDNA library, and selecting clones which encode segments of the antibody molecule; e.g. Wall et al., Nucleic Acids Research, Vol. 5, pgs. 3113-3128 (1978); Zakut et al., Nucleic Acids Research, Vol. 8, pgs. 3591-3601 (1980); Cabilly et al., Proc. Natl. Acad. Sci., Vol. 81, pgs. 3273-3277 (1984); Boss et al., Nucleic Acids Research, Vol. 12, pgs. 3791-3806 (1984); Amster et al., Nucleic Acids Research, Vol. 8, pgs. 2055-2065 (1980); and Moore et al., U.S. Patent 4,642,334. In particular, such techniques can be used to produce interspecific monoclonal antibodies, wherein the binding region of one species is combined with a non-binding region of the antibody of another species to reduce immunogenicity; e.g. Liu et al., Proc. Natl. Acad. Sci., Vol. 84, pgs. 3439-3443 (1987).

Antagonists of the invention are administered as a pharmaceutical composition. Such compositions contain a therapeutic amount of at least one of the monoclonal antibodies of the invention, or fragments thereof, in a pharmaceutically effective carrier. A pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivering the compositions of the invention to a patient. Sterile water, alcohol, fats, waxes, and inert solids may be included in a carrier. Pharmaceutically accepted adjuvants (e.g., buffering agents, dispersing agents) may also be incorporated into the pharmaceutical composition. Generally, compositions useful for parenteral administration of such drugs are well known, e.g. see Remington's Pharmaceutical Sciences, 15th Ed. (Mack Publishing Company, Easton, PA 1980). Alternatively, compositions of the invention may be introduced into a patient's body by implantable drug

-9-

delivery system; e.g. see Urquhart et al., Ann. Rev. Pharmacol. Toxicol., Vol. 24, pgs. 199-236 (1984).

When the antagonists of the invention are derived from antibodies, they are normally administered parenterally, preferably intravenously. Since such protein- or peptide-antagonists may be immunogenic, they are preferably administered slowly, either by a conventional IV administration set or from a subcutaneous depot.

When administered parenterally, the antibodies or fragments will normally be formulated with a pharmaceutically acceptable parenteral vehicle in a unit dosage form suitable for injection (solution, suspension, emulsion). Such vehicles are inherently nontoxic and nontherapeutic. Examples of such vehicles are normal saline, Ringer's solution, dextrose solution, and Hank's solution. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. A preferred vehicle is 5% dextrose/saline. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The antibody is preferably formulated in purified form substantially free of aggregates and other proteins at concentrations of about 5 to 30 mg/ml, preferably 10 to 20 mg/ml. For intravenous delivery, this may then be adjusted to a concentration in the range of about 1 to about 20 mg/ml.

Selecting an administration regimen for an antagonist depends on several factors, including the serum turnover rate of the antagonist, the serum level of IL-4 associated with the immune disorder, the immunogenicity of the antagonist, the accessibility of the target IL-4 (e.g. if non-serum IL-4 is to be blocked), the affinity of IL-4 to its receptor(s) relative to that of IL-4 to the antagonist, and the

-10-

like. Preferably, an administration regimen maximizes the amount of antagonist delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of antagonist delivered depends in part on the particular antagonist and the severity of the disease being treated. Guidance in selecting appropriate doses is found in the literature on therapeutic uses of antibodies; e.g. Bach et al., chapter 22, in Ferrone et al., eds., Handbook of Monoclonal Antibodies (Noges Publications, Park Ridge, NJ, 1985); and Russell, pgs. 303-357, and Smith et al., pgs. 365-389, in Haber et al., eds. Antibodies in Human Diagnosis and Therapy (Raven Press, New York, 1977). Preferably, the dose is in the range of about 1-20 mg/kg per day, especially when the antagonist comprises monoclonal antibodies or Fab-sized fragments thereof (including binding compositions). More preferably the dose is in the range of about 1-10 mg/kg per day.

The descriptions of the foregoing embodiments of the invention have been presented for purpose of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

-11-

Applicants have deposited E. coli MC1061 carrying pcD-human-IL4 with the American Type Culture Collection, Rockville, MD, USA (ATCC), under accession number 67029. This deposit was made under the Budapest Treaty (1977) on the International Recognition of the Deposit of Micro-organisms for the purposes of Patent Procedure.

-12-

WE CLAIM:

1. A method of reducing an immunoglobulin E response in a person comprising administering an effective amount of an antagonist to human interleukin-4.
2. The method of claim 1 wherein said antagonist to human interleukin-4 is selected from a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, and a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.
3. The method of claim 2 wherein said fragment of said monoclonal antibody is an Fab fragment.
4. The method of claim 2 wherein said monoclonal antibody is produced by a human-human hybridoma.
5. The method of claim 4 wherein said fragment of said monoclonal antibody is an Fab fragment.
6. The method of claim 2 wherein said step of administering includes intravenous delivery of said antagonist at a concentration in the range of about 1 to 20 mg/ml.
7. The method of claim 6 wherein said step of administering further includes intravenous delivery of an

-13-

amount of said antagonist in the range of about 1 to 20 mg/kg body weight of said individual per day.

8. Use of an antagonist to human interleukin-4 for the preparation of a therapeutic composition useful in reducing an immunoglobulin E response.

9. Use as claimed in claim 8 wherein said antagonist to human interleukin-4 is selected from a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, and a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.

10. Use as claimed in claim 9 wherein said monoclonal antibody is an Fab fragment produced by a human-human hybridoma.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US / 89/ 00285

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 4 A61K39/395 ; C12P21/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 4	A61K ; C12P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	PROC.NATL.ACAD.SCI.USA vol. 83, December 1986, page 9675 - 9678; FINKELMAN F.D. et al: "Suppression of in vivo polyclonal IgE responses by Mab to the lymphokine Bcell stimulatory factor1" see the whole document	1-10
X,P	JOURNAL OF IMMUNOLOGY vol. 141, no. 7, 01 October 1988, USA page 2335 - 2341; FINKELMAN F.D.: "IL-4 is required to generate and sustain in vivo Ig-E responses" see the whole document	1-10
<div style="display: flex; justify-content: space-between;"> <div> <p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
14 NOVEMBER 1989	30. 05. 89	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	AVEDEKIAN P. F. P.C.G. VAN DER PUTTEN	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	NATURE vol. 315, 23 May 1985, page 333 - 335; OHARA J. et al: "production of a monoclonal antibody to and molecular characterization of Bcell stimulatory factor1" see the whole document ---	1-10
A-P	EP,A,255547 (KISHIMOTO) see the whole document ---	1-10
A-P	EP,A,254767 (KISHIMOTO) see the whole document ---	1-10

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

PCT/US 89/00285

SA 26595

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 21/04/89

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-255547	10-02-88	EP-A- 0254767	03-02-88
		AU-A- 7619187	04-02-88
		EP-A- 0259585	16-03-88
		JP-A- 63258494	25-10-88
EP-A-254767	03-02-88	EP-A- 0255547	10-02-88
		AU-A- 7619187	04-02-88
		EP-A- 0259585	16-03-88
		JP-A- 63258494	25-10-88